stockrow
Saturday 7 November 2026
Export BBLG’s income statement to Excel — free account
Bone Biologics Corp.
BBLG Healthcare Biotechnology
- EPS
- +55.3%
- Free cash flow
- +9.99%
Quarter to September 2026, against a year earlier
0.33
0.01
+3.13%
Follow BBLG
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 | |
|---|---|---|---|---|---|
Current Ratio |
+8 more quarters Free account |
13.85 | 16.09 | 8.67 | 13.38 |
Net Debt/EBITDA |
7.28 | 5.63 | 4.99 | 9.14 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
1.04 | 1.05 | 0.67 | 0.86 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Free Cash Flow per Share |
(0.61) | (0.45) | (0.29) | (0.14) | |
Cash per Share |
4.54 | 2.52 | 2.24 | 1.63 | |
Shareholders Equity per Share |
4.58 | 2.60 | 2.18 | 1.59 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
4.58 | 2.60 | 2.18 | 1.59 | |
Free Cash Flow |
(0.71) | (0.80) | (0.52) | (0.53) | |
Working Capital |
5.38 | 4.67 | 3.92 | 5.95 | |
Net Current Asset Value |
5.38 | 4.67 | 3.92 | 5.95 | |
| Other line items | |||||
Quick Ratio |
12.77 | 14.67 | 7.89 | 12.68 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.61) | (0.45) | (0.29) | (0.14) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Payables |
0.40 | 0.28 | 0.46 | 0.41 | |
Average Assets |
4.83 | 4.07 | 5.72 | 6.39 | |
Average Common Equity |
4.43 | 3.79 | 5.26 | 5.98 |
Columns are period end dates · fundamentals updated 2 Nov 2026